Skip over main navigation
  • Log in
  • Basket: (0 items)
The Encephalitis Society

Support line: +44 (0)1653 699599

  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn
  • TikTok
  • Need help?
  • Join Us!
  • Donate
  • Twitter
Menu
  • Encephalitis explained
    • What is encephalitis?
    • Diagnosis of encephalitis
    • Types of encephalitis
      • Infectious encephalitis
      • Auto-immune encephalitis
      • Other
    • Being in hospital
    • Coronavirus and encephalitis
    • Effects
      • How the brain works
      • After-effects of encephalitis
      • Death from encephalitis
      • Effects on learning and school life
      • Mental health and encephalitis
    • Recovering from encephalitis
      • Guidelines for recovery
      • Practical strategies
      • Rehabilitation after encephalitis
      • Professionals involved in recovery
      • Neuropsychological assessment
    • Infectious encephalitis and travel
  • Get Help
    • Get support (now)
    • Get information
      • Encephalitis in adults
      • Encephalitis in children
      • Encephalitis in young people
      • Information for carers & family
      • Dealing with bereavement
      • Information for teachers
      • Information for health professionals
      • Helpful books
      • Crisis lines worldwide
    • Legal advice
    • Meet other people affected
    • Events and activities
  • Stories and News
    • Our campaigns
      • World Encephalitis Day
      • Encephalitis Information Week
      • Research month
      • Measles FAQ
      • BBC Radio 4 appeal
      • Hollyoaks
      • Encephalitis Matters petition
    • Our projects around the world
    • Our blog
    • Your stories
    • Our Podcasts
    • My brain and me
    • Newsletters
  • Encephalitis research
    • Global Impact Report
    • Events for professionals
      • Masterclass webinars
      • External events
    • Grants
      • International Research Seed Funding
      • MRC fellowship
      • Current grants/projects
      • Completed grants/projects
      • Information for researchers
    • Resources for health professionals
      • Research Summary
      • Professional Newsletter
      • Professional guidelines
      • Patient resources in different languages
    • Research currently recruiting
    • Professional membership
    • Training and consultancy
  • Support Us
    • Fundraise for us
      • Our fundraising events
      • Do your own thing
    • Donate now
    • Ways to give
      • Write your Will for free
      • Gift Aid
      • Unity Lottery
      • Trusts and foundations
      • Other ways to give
    • Membership
    • Volunteer
    • Our Partners
    • WED partners
    • Corporate engagement
    • Changemakers
  • Shop
  • About us
    • Our vision
    • Our team
      • Our Ambassadors
      • Our President / VPs
      • Our Scientific Advisory Panel
      • Our Trustees
      • Our Staff
    • Our previous events
    • Our impact
    • Our accounts
    • Our policies
    • Current vacancies
    • Media Centre
  • Encephalitis Conference
  • My Brain: My Story - 7 October 2023
  • 01653692583
    • Log in
  • Basket: (0 items)
  • research-currently-recruiting
  1. Encephalitis research
  2. Research currently recruiting

Research currently recruiting

Get involved in one of the following research projects!

If you are interested in taking part in research, please have a look at the following research projects on encephalitis and its consequences. If you have further question about any of these projects, please contact the lead-person advertised in the project summary. 

Disclaimer: The Encephalitis Society is encouraging, supporting and funding scientific research into the condition, from diagnosis, treatment through to recovery and rehabilitation. By helping to find participants for research studies, Encephalitis Society is not taking any responsibility for the research and is therefore not liable for any claims concerning negligence, harm or oversight that might arise during the course of the research.

Brain scans to investigate NMDA receptor antibody encephalitis in children and young people

Can you help researchers at Kings College London to learn more about NMDA receptor antibody encephalitis in children and young people

Expand

Can you or your child help us learn more about NMDA receptor antibody encephalitis?

Are you aged between eight and 24-years-old?

Would you like to earn up to £80 in gift vouchers?

Then you may be able to help researchers at Kings College London develop advanced brain MRI scans so they can better investigate autoimmune encephalitis in children and young people.

The research team are recruiting two groups:

  • Youngsters who have been diagnosed with Anti-NMDAR encephalitis in the past 12 months, or had a relapse (new attack) of anti-NMDAR encephalitis in the past 12 months
  • Healthy youngsters without an encephalitis diagnosis (to act as control group)

Travel expenses will be reimbursed – with the tokens offered as a thank you for taking part.

The MRI scans will take place at St. Thomas’ Hospital, London.

Dr Michael Eyre, of Kings College London, said MRI is a safe imaging technology with participants able to listen to music or watch Netflix during the scan.

“We will assess if these scans, combined with tests of memory, thinking, mental health and functioning in daily life, can help predict the outcome of autoimmune encephalitis for the individual person,” he said.

“We hope our results will ultimately help doctors select the best treatment for each patient, improving the chances of controlling their symptoms sooner, shortening hospital stays and reducing the long-term effects on their lives,”

To find out more and take part, email Dr Eyre at [email protected]

Email Dr Michael Eyre

Published: 29th April, 2022

Updated: 9th March, 2023

Author:

Share this page
  • Email
  • Facebook
  • Twitter

Episodic memory loss following LGI1-limbic encephalitis

Expand

Institution: UCL/National Hospital for Neurology and Neurosurgery, London

Lead researcher: Dr Thomas Miller [email protected] 

Neurologists at UCL/National Hospital for Neurology and Neurosurgery – based in Central London – are recruiting patients that have recovered from LGI1-limbic encephalitis and have memory difficulties to take part in a study.

The study is a functional MRI study that is trying to visualise how memory processes become affected after the disease.

This involves some neuropsychology testing and retrieval of memories from your life, some of which you will then be asked to recall during MRI scanning.

What key criteria should participants meet (e.g. age, type of encephalitis, geographical location)?

  • Patients who have tested positive for LGI1 antibodies only
  • Adults aged between 18-70 years of age.
  • Free of clinical symptoms and be considered clinically stable by their responsible consultant neurologist. This is usually about one year from the onset of their acute illness.
  • Not on any medication to treat their condition such as prednisolone or psychoactive medication. Ideally, patients will be no longer be taking epilepsy-controlling medication.
  • Patients should be seizure-free.
  • Patients should report some degree of episodic memory difficulties in their day-to-day life.
  • Patients should self-report as healthy and free of secondary gain or active psychopathology.
  •  All participants should be fluent in English.

What will taking part involve for the participants? (schedule of activity i.e. if home visits possible, length  of visits, medication changes)

Initially, some memory testing performed at home alongside retrieval of patients own memories. These can be done on the same visit or on two separate visits (depending on patient preference). These take about 1.5 hours each. Then there is the visit to our Centre for the scan which takes about 2.5 hours from walking in to leaving again (and including breaks).

Are you looking for a control group? If so, what is the criteria?

Yes - healthy control participants will be matched on the basis of age, gender, educational level, and on general neuropsychological measures.

 Will participant expenses be reimbursed?                                                            

Yes, we cover their time and if need be travel and accommodation.

For more information please contact Dr Tom Miller ([email protected]).

Published: 20th January, 2023

Author:

Share this page
  • Email
  • Facebook
  • Twitter

LEGIONE Study

Expand

Aims: LEGIONE is a 34-week study that is evaluating whether an investigational medication called rozanolixizumab is well tolerated and effective in treating LGI1 autoimmune encephalitis. This drug is also being studied in other conditions that involve the immune system.

Institution:  This study is sponsored by UCB, a global biopharma company focusing on immunology and neurology disorders, including autoimmune diseases.

Location: LEGIONE will be taking place at sites in several different countries all around the world (Australia, Belgium, Canada, France, Germany, Italy, Korea, Netherlands, Portugal, Spain, Turkey, United Kingdom, USA). You can use this link below to search for the site closest to you and see their contact information.

https://aielegione.com/locations  

What key criteria should participants meet

  • Be between 18 and 89 years old
  • Have tested positive for anti-LGI1 antibody
  • Have symptoms that started within the last 12 months and include facio-brachial dystonic seizures (FBDS) and/or other partial (focal) seizures, unless they stopped as a result of current intravenous methylprednisolone (IVMP) treatment
  • Be considered suitable for treatment with IVMP or have started treatment with IVMP

What will taking part involve for the participants?

The study will take place over 34 weeks and includes screening ( finding out if you are suitable for the study), study treatment period and safety follow-up period (monitoring).

Clinical studies are completely voluntary, and participants can leave at any time without losing any benefits they would normally be entitled to.

Will participant expenses be reimbursed?                                                           

You will be reimbursed for reasonable travel expenses as appropriate.

If you are interested in taking part, or you think someone you care about may be suitable for the study, talk to your doctor. They may be able to discuss the study with you and talk you through the potential benefits and risks of being involved before you make your decision about participating.

Alternatively, please check contact details for the closest site and get in touch https://aielegione.com/locations

 For more information about the study  https://aielegione.com/

 

 

 

 

Published: 28th July, 2023

Author:

Share this page
  • Email
  • Facebook
  • Twitter

CIELO study

Expand

Aims: The purpose of this study is to assess the effectiveness and safety of satralizumab in participants with anti-NMDAR and anti-LGI1 encephalitis.

Institution:  This study is sponsored by Hoffmann-La Roche, one of the world’s largest biotech companies

Location: This trial runs in 11 countries: Argentina, Austria, China, Czechia, Denmark, Italy, Japan, Poland, South Korea, Taiwan and United States

What key criteria should participants meet

  • Be at least 12 years old and have been diagnosed with anti-NMDAR OR at least 18 years old and be diagnosed with anti-LGI1
  • Symptoms started no longer than nine months ago.

Who cannot take part

·       People may not be able to take part in this trial if they have a history of cancer or certain other medical conditions, or if they have been treated with particular medications.

·       People who are pregnant or breastfeeding will not be able to take part in this clinical trial.

What will taking part involve for the participants?

Everyone who joins this clinical trial will be put into one of two groups randomly and given either satralizumab or placebo (substance with no active ingredients) as a subcutaneous injection at weeks 0, 2 and 4, and then every four weeks until week 52. Participants will have a 50% chance of being placed in either the satralizumab or placebo group. Comparing results from the different groups helps the researchers know whether any changes seen are a result of the drug or occurring by chance.

Participants will be seen by the clinical trial doctor every four weeks to be given their clinical trial treatment. These hospital visits will include checks to see how the participant is responding to the treatment and any side effects they may be having.

How long will the trial last?

Depending on whether participants choose to take part in an optional extension period of the trial (which will last for at least two years), their total time in the clinical trial may last for up to five years (including follow-up appointments). Participants are free to stop trial treatment and leave the clinical trial at any time.

Will participant expenses be reimbursed?       

You may be reimbursed for any reasonable travel expenses                                                    

How do I take part?

If you are interested in taking part, or you think someone you care about may be suitable for the study, talk to your doctor. They may be able to discuss the study with you and talk you through the potential benefits and risks of being involved before you make your decision about participating.

For more information about the study or if you would like to contact a center in your country https://forpatients.roche.com/en/trials/autoimmune-disorder/autoimmune-encephalitis/a-study-to-evaluate-the-efficacy--safety--pharmacokinet-99237.html

 

 

Published: 11th September, 2023

Author:

Share this page
  • Email
  • Facebook
  • Twitter

Predictors and psychological outcomes associated with perceived boundary ambiguity in families affected by acute, non-progressive neurological conditions

Expand

Lead Researcher: Mariann Kovacs

Institution: University of Oxford

If you are the partner or spouse of someone who has had a brain injury (such as encephalitis), please consider participating in an ongoing research project that explores how your well-being and relationship satisfaction have been affected since your partner’s brain injury,

The results will shape future clinical practice and service provision for families affected by a brain injury/stroke. 

WHAT IT INVOLVES: two online surveys, completed 3 months apart

For more information, follow http://tinyurl.com/lifepostinjury

Published: 11th September, 2023

Author:

Share this page
  • Email
  • Facebook
  • Twitter
Back to top

Latest

  • WEDA Conference - Empowering Hope

    WEDA Conference - Empowering Hope

    A three-day World Encephalitis Day event in Jacksonville, Florida, in February 2024. Brought to you by The World Encephalitis Day Alliance

  • Baroness Fiona Twycross

    Baroness Fiona Twycross

    Baroness (Fiona) Twycross was appointed to the House of Lords in November 2022. She is Education Spokesperson in the Lords and a Labour Whip.

  • Predictors and psychological outcomes associated with perceived boundary ambiguity in families affected by acute, non-progressive neurological conditions

  • CIELO study

Most read

  • NMDAR antibody encephalitis

    NMDAR antibody encephalitis

    NMDAR antibody encephalitis is an autoimmune disease that causes psychiatric features, confusion, memory loss and seizures followed by a movement disorder, loss of consciousness and changes in blood pressure, heart rate and temperature.

  • Herpes Simplex  virus encephalitis

    Herpes Simplex virus encephalitis

    Herpes simplex encephalitis is a type of infectious encephalitis which happens when herpes simplex virus (HSV) enters the brain. Usually, it begins with ‘flu-like’ symptoms followed by neurological deterioration, which may include personality and behavioural changes, seizures, weakness and difficulties in communication.

  • What is encephalitis?

    What is encephalitis?

    Encephalitis is an inflammation of the brain caused by an infection or through the immune system attacking the brain in error.

  • Guidelines for recovery

    Guidelines for recovery

    No two people with encephalitis have the same outcomes. People recover at different paces. Recovery can be helped by having lots of rest, good nutrition, helpful social network and support from professionals.

  • Limbic encephalitis

    Limbic encephalitis

    The term ‘limbic encephalitis’ (LE) describes the condition when limbic areas of the brain are inflamed (swollen) and consequently not functioning properly. Most forms of LE fall into two main categories: infectious encephalitis and autoimmune encephalitis.

  • Death from encephalitis

    Death from encephalitis

    Encephalitis is a serious neurological condition and unfortunately, despite improvements in specific and more supportive treatments such as excellent intensive care management, encephalitis still has a high mortality (death) rate.

  • Encephalitis: after-effects, recovery and rehabilitation

    Encephalitis: after-effects, recovery and rehabilitation

    This booklet provides key information about the type of issues that people may have after encephalitis, why rehabilitation/support from professionals and families are important and what options for self-help are available.

  • West Nile encephalitis

    West Nile encephalitis

    West Nile encephalitis is a type of infectious encephalitis caused by West Nile virus. People usually become infected after being bitten by a mosquito, which has fed on an infected bird.

  • Emotional and behavioural changes

    Emotional and behavioural changes

    Following encephalitis, some people may experience emotional and behavioural changes including low mood, increased anxiety, depression, mood swings, frustration, aggression, impulsivity, disinhibition, and/or poor emotional regulation.

  • Get support

    Get support

    Our Support Service is here to help you with any questions about encephalitis, recovery and rehabilitation or emotional support.

Tag cloud

About Us Anne McIntosh anti-nmdar Brain on Fire Case Studies encephalitis blog Japanese encephalitis limbic NeuroAccess Story support Tick-borne encephalitis volunteer
    • Twitter
    • Facebook
    • Instagram
    • YouTube
    • LinkedIn
    • TikTok
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Cookie Policy
  • Complaints Policy
  • Accessibility
  • Media Centre

Contact us

Encephalitis Society, 32 Castlegate,
Malton, North Yorkshire YO17 7DT
United Kingdom
T: +44(0)1653 692583
E: [email protected] (general enquiries)
E: [email protected] (support enquiries)
Directions

The Encephalitis Society is the operating name of the Encephalitis Support Group which is a registered Charity and Company Limited by Guarantee.

Registered in England and Wales No. 04189027. Registered Office as above. Registered Charity No. 1087843. Registered Charity in Scotland: SC048210

Keep up to date with out latest news

Please enter your first name
Please enter your last name
Please enter your email address Please enter a valid email address (e.g. [email protected])


We automatically make you a member which is free and supports our work, you can opt out at any time.
Manage Cookie Preferences